Structure Therapeutics Inc. ADR (GPCR) News
Filter GPCR News Items
GPCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GPCR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest GPCR News From Around the Web
Below are the latest news stories about STRUCTURE THERAPEUTICS INC that investors may wish to consider to help them evaluate GPCR as an investment opportunity.
Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss market. |
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of ObesityPreclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global bioph |
Is Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds?We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at […] |
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ StocksThere’s been something of a sea change in the economic outlook for 2025, in the aftermath of last month’s election. The prospect of a second Trump administration, with his known preference for deregulation and tax cuts, has market watchers expecting a growth-friendly environment. Desh Peramunetilleke, Jefferies’ Global Head of Quantitative Strategy, notes that reduced regulation, combined with the potential for lower corporate tax rates, could significantly boost the biotech sector, with smaller |
Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts?We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against the other up and coming stocks. Donald Trump’s victory in the recent presidential election is expected to encourage companies that […] |
Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to AnalystsWe recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined CNBC’s ‘The Exchange’ on November 16 to discuss where he […] |
Structure Therapeutics to Participate in the Jefferies London Healthcare ConferenceSAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK. Jefferies London Healthcare Conference Format:Presenta |
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent HighlightsFirst patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- |
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for ObesityPhase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeu |
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced multiple upcoming posters at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 3-6, 2024 in San Antonio, TX. Title: Novel Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists for Obesity TreatmentPoster Number: P |